MedTrace Logo

High-flow Nasal Oxygenation and Non-invasive Ventilation Strategies for the Treatment of Covid-19 Pneumonia

NCT05137431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-08-11

No results posted yet for this study

Summary

HFNO and NIV strategies are the most commonly used strategies for the treatment of hypoxia in patients with a diagnosis of COVID-19 who are still followed in the intensive care unit, but there is no study comparing the two yet. In our prospective study, we aimed to compare these two treatment modalities. The primary goal is that the treatment is successful (weaned off HFNO/weaned off NIV: No need for HFNO or NIV and the patient recovers without the need for intubation). Failure will be evaluated as the need for intubation during treatment or the patient's death. Secondary aim is failure of treatment and discharge of patients from intensive care to service or home.

Conditions

Interventions

OTHER

HFNO and NIV

Patients meeting the inclusion criteria will be treated alternately with 2 hours of HFNO and 1 hour of NIV (HFNO-NIV for the same patient in turn). In 24 hours, there will be 16 hours of HFNO, 8 hours of NIV. Parameters to record * Respiratory parameters (respiratory rate) * SpO2 * Ventilator settings * Patient's tolerance (VAS; between 0-100) * Arterial blood gas (HFNO and NIV at 1 hour) * Clinical parameters (D dimer, CRP, ROX index) Intubation criteria * Loss of consciousness * Agitation * Persistent hypotension * Need for fluid resuscitation * Need for vasopressor * Respiration rate ≥40/min * SpO2 \<92 * pH\<7.30

Sponsors & Collaborators

  • Medipol University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-08
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137431 on ClinicalTrials.gov